Skip to main content
. Author manuscript; available in PMC: 2022 Feb 10.
Published in final edited form as: J Control Release. 2020 Nov 11;330:1095–1105. doi: 10.1016/j.jconrel.2020.11.014

Fig. 1.

Fig. 1.

Illustration shows (A) the functional synergy of the STING agonist (cdGMP) and TLR4 agonist (MPLA) to activate the signaling pathways leading to the induction of potent cytokines including Type I interferons, and (B) the immunostimulatory nanoparticle loaded with the dual-agonist cargo of cdGMP and MPLA.